IMMP News and Press, Immutep Limited From 12/16/21

Immutep (NASDAQ:IMMP) has signed a Manufacturing Service Agreement (MSA) with Northway Biotech to manufacture IMP761 ahead of clinical testing. Under the agreement, Northway has already started developing a GMP-compliant manufacturing process of IMP761 and will manufacture the drug in large s...

Immutep (NASDAQ:IMMP) announces the first five patients have been treated in the INSIGHT-003 study. Shares up 2.2% premarket at $3.30. No additional safety signals have been observed in the study which is the first time a triple combination therapy consisting of eftilagimod alpha (ȁ...

SYDNEY, AUSTRALIA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the first fiv...

Enrolled and dosed last patient in the expansion stage of Part A (1 st line non-small cell lung cancer (NSCLC)) needed to complete recruitment into all cohorts of the TACTI-002 study Interim data from Part C (2 nd line head & neck squamous cell carcinoma (HNSCC) patients) ...

AIPAC poster presentation includes new data and graphs showing: Very encouraging Overall Survival (OS) data from the abstract published on 9 November 2021, including statistically significant benefit in 3 patient subgroups representing a majority of patients A statistically si...

SYDNEY, AUSTRALIA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce ...

RenovoRx (NASDAQ:RNXT) +68% after presentation on treatment platform RingCentral (NYSE:RNG) +26% after boosting full-year revenue outlook; buys Mitel's IP rights and patents Valneva SE American Depositary (NASDAQ:VALN) +25% on European nod to procure up to 60M do...

Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcement Encouraging Objective Response Rate (ORR) of 29.7% (11/37), including 5 Complete Responses in 2 nd line head and neck squamous cell carcinoma (HNSCC) patients in Part C of Phase I...

Final Overall Survival (OS) data supports Phase III clinical development of efti in combination with paclitaxel in metastatic breast cancer OS benefit trend in total population, with median survival benefit of +2.9 months from efti plus chemotherapy, compared to chemotherapy plus plac...

Immutep (NASDAQ:IMMP) announces the grant of a new patent entitled "use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response" by the Chinese Patent Office. The patent forms part of a broad portfolio of patent families for the company’s lead prod...